


Imaging and interpretation of radiobiological processes


Marco Ravanelli, Roberto Maroldi
marcoravanelli@hotmail.it





Imaging and biology




Imaging*target matrix



Biological targets

- Hypoxia
- Angiogenesis
- Interstitial fluid pressure (IFP) 
- Cell proliferation
- Apoptosis/Necrosis
- Tumor stroma 




Imaging “weapons”

- PET:

- FDG Direct
- MISO Direct
- FLT Direct


- MRI:

- DCE/perfusion MRI
- DWI
- IVIM DWI



dynamic relaxivity contrast enhanced MRI (DCE-MRI)

- noninvasive quantitative method
- investigates **microvascular structure and function** by tracking the pharmacokinetics of injected Gd contrast agents as they pass through the tumour vasculature
- the technique is sensitive to alterations in
 - vascular permeability (K_{trans})
 - extracellular extravascular volume (v_e, F_{is})
 - vascular volume (BV)
 - blood flow (BF)



DWI-MRI → tissue cellularity, extracellular space tortuosity, and integrity of cellular membranes

- water motion in tissues → modified by
 - flows within conduits (for example, blood vessels, glandular ducts, etc.);
 - interactions with cellular components (hydrophobic phospholipid-containing cellular membranes, intracellular organelles, and macromolecules)
- DW “made” sensitive to large/small displacements of water:
 - Large → macroscopic flows (**low b-values <50–100 s/mm²**),
 - Small → microscopic extracellular space/intracellular water displacements (**high b-values**)
- DW gradients to standard T2-w sequences (b-values)
- ADC measures water motion restriction (high ADC → low restriction; low ADC → high restriction)



DWI IVIM

- DWI signal is influenced by
 - a fast component due to arteriolar blood flow [Lemke et al 2009]
 - A slow component due to interstitial water diffusion
- Biexponential analysis of DWI signals allows perfusion- from diffusion-effect to be separated
- Perfusion is described by f (*perfusion fraction*) and D^* (*pseudodiffusion coefficient*)



IFP



- Largely variable in all histologies
- Cervical cancer has been the most studied human model, followed by head and neck cancer
- Studies in vivo on human melanoma, cervical and breast cancer xenografts


Tumor type	n	Mean	Range
Normal skin	5	0.4	-1.0 to 3.0
Normal breast	8	0.0	-0.5 to 3.0
Head and neck carcinomas	27	19.0	1.5 to 79.0
Cervical carcinomas	127	20.5	-2.8 to 94.0
Lung carcinomas	26	9.5	1.0 to 27.0
Metastatic melanomas	26	18.0	0.0 to 60.0
Breast carcinomas	21	23.7	4.0 to 53.0
Brain tumors	28	4.6	-0.5 to 15.0
Rectal carcinoma	8	15.3	12.1 to 15.8
Colorectal liver metastasis	8	21.0	6.0 to 45.0
Lymphomas	7	4.5	1.0 to 12.5
Renal cell carcinoma	1	38.0	-



IFP

Links with angiogenesis and hypoxia:


- + correlation between IFP and central hypoxic fraction
- + correlation between IFP and peripheral MVD (CD31)
- Critical IFP level: 20 mmHg



Rofstad et al 2014



Peritumor edema





IFP

- Correlation with radiocurability in xenografts: TCD₅₀ 20% higher in high IFP (>8 mmHg) [Rofstad et al 2009]
- Correlation with radiocurability in xenografts without hypoxia: TCD₅₀ 13% higher in high IFP [Rofstad et al 2010]
- → hypoxia related and non-related effects
- Prognostic factor in cervical cancer [Fyles 2006; Yeo 2009; Hockel 1996 and 1999; Lyng 2000; Knocke 1999]
- Benefit from cisplatin addition to RT in high IFP cervical cancer [Milosevic et al 2014]



DWI → IFP



- ADC inversely correlated with IFP
- ADC inversely correlated with hypoxic fraction
- ADC inversely correlated with tumor cell density
- Cell density correlated with IFP and hypoxia



IVIM DWI → IFP

- IFP correlates with IVIM metrics in a mouse mammary carcinoma model

	All voxels		AVV only	
	<i>r</i>	<i>p</i>	<i>r</i>	<i>p</i>
ADC	0.06	0.87	0.11	0.78
D_t	0.18	0.64	0.30	0.44
f_p	0.35	0.36	0.34	0.37
D_p	0.70*	0.04	0.76*	0.02
$f_p:D_p$	0.70*	0.03	0.77*	0.02



Kim et al 2012



DCE → IFP




- Microvessel permeability (K_{trans}) is inversely correlated to IFP [Hompland et al 2013; Haider et al 2007]
- As suggested also from IVIM studies, high IFP neg affects perfusion and oxygenation of tumor
- Mathematical models suggest possible role of antiangiogenic drugs in normalizing interstitial hypertension [Jain et al 2007] → association with radiotherapy?

Kim et al 2012



DCE → peritumor edema




- Peritumoral interstitial fluid flow velocity measured by DCE-MRI predicts survival in cervical carcinoma (62 pts)
- Velocity of outward expansion of peritumoral enhancement



Hompland et al 2013




IVIM → peritumor edema




	21	9
F(%)	21	9
D ($\times 10^{-3}$ mm ² /s)	1.67	0.82

IVIM → peritumor edema




tumor hypoxia Direct



- acute: perfusion-related
- chronic: diffusion-related, increased diffusion distance more than 70-100 μm
- Promotes angiogenesis, adaptation and immortalization via HIF-1



Intratumoral hypoxia



Genetic alterations



cyclic hypoxia (pre-clinical)

- cyclic acute: cyclic fluctuations in tumor oxygenations given by acute hypoxic followed by reoxygenation phases;
- hypoxic phases: HIF-1 α accumulation in endothelial cells;
- reoxygenation phases: signalling cascade leading to phenotypic changes, genome instability.

- incremented angiogenesis
- increased metastatisation
- immortalization

- increment of cancer stem cells (CSC) population



acute cyclic hypoxia (in vivo)

- *In vivo*, acute cyclic but not chronic hypoxia induced increased metastatisation [Cairns et al 2001]
- acute cyclic hypoxia enhances angiogenesis [Gaustad et al 2013]
- tumors exposed to acute hypoxia are more radioresistant than chronicall hypoxic tumors [Denekamp et al 1999]
- chronic and cycling hypoxia differently affect different hystotypes [Ellingsen et al 2012]

need for techniques capable to measure hypoxia and separate acute cyclic from chronic hypoxia



hunting for hypoxia

- oxygen probes (computerized pO₂ histography) demonstrated that hypoxia is not dependent on size, stage, histology and grade in uterine cervix cancer. [Vaupel et al 2001]
- hypoxic areas are heterogeneously distributed in the tumor [Vaupel et al 2004].

whole tumor individual assessment (imaging)



Optimal (imaging?) technique

- **Quantitative:** effectiveness of different therapies becomes impaired at different pO₂ levels [Hockel et al 2001], 0-15 mmHg level seems to be critical.
- **Sensitive** to small pO₂ changes.
- **Specific:** **Direct** on hypoxia or on specific hypoxia effects.
- Able to separate **chronic, acute/cycling** hypoxia and anoxic necrosis.
- Able to image the **whole tumor** (not only superficial tumors).



possible strategies

- assessment of tumour oxygenation **Direct**
 - pO₂ measurement
 - oxygenation-dependent biological pathways
- assessment of hypoxia phenotypes **Surrogate**
 - perfusion assessment



- Nitroimidazole based: ^{18}F MISO (FDA approved), ^{18}F FAZA, ^{18}F FETA etc.
- Etanidazole based: EF3-EF5
- ^{64}Cu ATSM (FDA approved): higher signal to background ratio, 12h half-live
- **HX4: most promising**
- FDG: non specific.
FDG uptake does not correlate with hypoxia specific stainings/tracers uptake.




F-18–fluoromisonidazole (F-MISO PET)

- most commonly used radiotracer in hypoxia imaging;
- misonidazole passively diffuses into the cells:
 - in the presence of oxygen, the last reaction is reversible and the molecule can leave the cell,
 - in absence of oxygen, misonidazole is reduced and remains trapped in the cell.
- also an efficient hypoxic radiosensitizer;



^{18}F MISO PET



- No differentiation between chronic and acute cycling hypoxia
- Seems to be affected by both [Monnich et al 2012]




Hypoxia/metabolism geographical mismatch

- HX4 PET on 20 head and neck cancer patients
- 13/20 hypoxic
- Hypoxic usually smaller than metabolic subvolumes (51%±26%)
- In 9/13 25%±21% of hypoxic subvolume was outside metabolic subvolume
- → FDG PET cannot be used as surrogate of hypoxia imaging
- Similar results on NSCLC [Zegers et al 2014]



Hypoxia (t)




Lin et al 2008



MR world Direct

- Electron paramagnetic resonance imaging (EPRI) and Overhauser MRI (OMRI): measures redox status of injected nitroxides or trytil radical, determined by tissue molecular oxygen
- High temporal resolution allows detection of cyclic hypoxia



Krishna et al 2013




MRI world Surrogate

- BOLD MRI (usable in clinics):
 - does not measure pO₂ (no linear relation), but deoxyhemoglobin concentration
 - flow-dependent → sensitive to acute hypoxia
 - flow-dependent → influenced by regional blood flow
 - relatively insensitive to chronic hypoxia (occurring in non-flowing blood regions)
 - Poor quantitative correlation with pimonidazole staining



DCE MRI

- Correlates with hypoxic fraction and radioresponsiveness in cervical carcinoma xenografts



DCE MRI **Surrogate**

- Data confirmed in vivo on xenografts by several studies
- Except: poor correlation in rectal cancer [Atkin et al 2006; Kim et al 2013]
- Correlation between DCE MRI and hypoxia markers in humans is emerging in:
 - cervical cancer [Halle et al 2012]
 - prostate cancer [Borren et al 2013]
 - gliomas [Jensen et al 2014]



Hypoxia imaging

- Prediction and prognostic risk stratification:
 - FMISO: Sato et al 2014 (H&N), Trinkaus et al 2014 (H&N), Zips et al 2013 (H&N), Hugonnet et al 2011 (kidney) Rischin et al 2006 (H&N), Eschmann et al 2005 (NSCLC)
 - DCE MRI: Jensen et al (gliomas), Halle et al 2012 (cervix), other studies but without hypoxia specific evaluation
- Promising results for objective response and progression-free survival, not for overall survival



Angiogenesis

- MVD (CD31) the most used marker
- Radiosensitivity: high MVD associated with higher radiosensitivity in early laryngeal cancer [Kamijo et al 2000] and metastatic cervical lymph nodes from HNSCC [Ito et al 2011]
- Outcome (MVD, multimodal treatment): no correlation with outcome in HNSCC [Calvin et al 2007; Foote et al 2005], poor prognostic factor in breast cancer [meta-analysis, Uzzan et al 2004; Gasparini et al 2001], renal cancer [meta-analysis, Cheng et al 2014; Zhang et al 2014] and CRC [Des Guetz et al 2006]



Angiogenesis

- MVD seems to be positively correlated with radiosensitivity and poor prognosis!!!

REVIEW

Clinical Application of Antiangiogenic Therapy: Microvessel Density, What It Does and Doesn't Tell Us


Lynn Hlatky, Philip Hahnfeldt, Judah Folkman

- MVD describes number of vessels per hotspot but not vessel function neither angiogenetic activity
- Furthermore, microvascular heterogeneity must be taken into account



DCE-MRI

- Non pharmacokinetic quantitative analysis (highly enhancing pixel fraction at 60 sec), 85 pts, advanced cervical cancer




- Similar results (K_{trans}) confirmed in other studies [Mayr et al 2011]
- DCE-MRI provides information about vascular function, correlating with angiogenetic activity

Lund et al 2015



DWI → Cell proliferation

- 93 NSCLC, pre treatment DWI, ADC min



- (Known correlation with cell density)
- Also observed in breast cancer [Molinari et al 2015]




Karaman et al 2015



Direct

FLT PET → proliferation



- Thymidine salvage way (DNA precursors supply)
- Dependent on TK1 activity (late G1-S phase)
- Non linear and heterogeneous relationship with cell proliferation
- Correlation demonstrated in: lung cancer, B-lymphoma, skin cancer but not in: CRC, neuroblastoma and several xenograft models
- Prognostic prediction in high grade glioma [Idema et al 2012] et lymphoma [Hermann et al 2011]



McKney et al 2013; Zhang et al 2012

FLT-PET → repopulation

- Yue et al (2010) demonstrated increase FLT uptake in 2 pts after RT interruption
- Everitt et al (2009) observed a 'flare' of 18F-FLT uptake in NSCLC following only 2 Gy irradiation
- Fatema et al (2013) demonstrated gradual increase of FLT uptake in HNSCC xenografts since 6 hr after treatment



Necrosis/apoptosis

- Possible biomarker of treatment efficacy
- Early assessment with DWI during treatment.
- Rationale for DWI is increase water diffusivity due to cell membrane rupture
- Increase in ADC during treatment is sign of response
- ADC changes <10-15% are *technically* non significant because of low test re-test repeatability



DWI during-Chemo-RT & post-ChemoRT


early PET CT
SE 83% SP 54%

reference	year	type	pts	T	N	time
Vandecaveye	2010	pro	30	Δ ADC > 14%	Δ ADC > 14,6%	2 weeks
				SE 88% SP 91%	SE 80% SP 89%	
				Δ ADC > 25%	Δ ADC > 19%	4 weeks
				SE 100% SP 91%	SE 80% SP 96%	
King	2009	pro	20 (50)	ADC < 1,43 × 10 ⁻³ mm ² /s SE 45% SP 100%		6 weeks post treatment end
Kim	2009	pro	33	Δ > 11%	ADC < 1.11 SE 65% SP 86%	pre Tx
Vandecaveye	2007	pro	26	ADC > 1,3 × 10 ⁻³ mm ² /s SE 94% SP 95%		post treatment end
Razek	2006	pro	32	ADC < 1,3 × 10 ⁻³ mm ² /s SE 84% SP 90%		post treatment end
Kato	2009	retro	28	ADC correlates with regression rate (r -0.37)		pre treatment





Tumor stroma

- Strong prognostic variable in lung adenocarcinoma [Maeshima 2002], gastric cancer [Wu 2013], triple-negative breast cancer [Moorman 2012]
- Complex interactions with angiogenesis, hypoxia, immunity
- Complex and debated role in radiosensitivity [Ogawa et al 2007]




DCE CT and tumor stroma

- Fis describes contrast accumulation in the interstitium
- Strong dependence on tumor histotype




Koyasu et al 2015




DWI and tumor stroma

- Heterogeneous results
- Heterogeneous histology: collagen-dominant, fibroblasts-dominant, lymphocyte-dominant
- Possible role for direct targeting with PET [Blykers 2015]



Breast ER+ cancer [Ko et al 2014]




Laryngeal cancer [Driessen 2014]



Tumor heterogeneity

- Inter-tumor heterogeneity
- Intra-tumor heterogeneity (multiclinality, stochastic genetic or epigenetic events, microenvironmental pressure fluctuations)
- Heterogeneity among tumor and its metastases




The *Lombrosian* hypothesis

- Imaging depicts tumor heterogeneity at phenotypic level
- *Phenotypic tumor heterogeneity reflects genetic, epigenetic, microenvironmental heterogeneity*
- Genetic, epigenetic, microenvironmental heterogeneity influences treatment response
- imaging can predict treatment response




DWI heterogeneity in OPSCC

- 27 pts with advanced oropharyngeal cancer treated with CHT-RT
- Histogram analysis on DWI before treatment
- ADC skewness and max on T correlated with prognosis (skew*max had RR=15.45 for OS, p<0.0001)
- Critical issues:
 - repeatability
 - tumor segmentation



CT heterogeneity in NSCLC

- Retrospective study on 53 pts with advanced NSCLC
- Texture analysis on *pre-treatment* contrast-enhanced CT
- CT density and Uniformity predicted objective response to CHT
- Possible patient stratification



Ravanelli et al 2013



filtration-histogram approach (literature overview)

- Colorectal cancer: hepatic CT on portal phase-baseline [Ganeshan et al 2007]
- Breast cancer: MR-early assessment [Parikh et al 2014]
- Oesophageal cancer: unenhanced CT-baseline [Ganeshan et al 2012]
- NSCLC: unenhanced CT-baseline [Ganeshan et al 2012];
NSCLC: contrast-enhanced CT-baseline [Ravanelli et al 2013]
- Renal cancer: contrast enhanced CT-early assessment (antiangiogenic drugs) [Goh et al 2011]
- H&N: contrast enhanced CT-baseline [Zhang et al 2013]



CT heterogeneity in CRC liver mets

- 23 pts CHT + bevacizumab, 20 pts CHT
 - Texture analysis on *pre-treatment* contrast-enhanced CT
 - Correlation with objective response, PFS and OS
 - In pts treated with bevacizumab, high uniformity correlated with poor response rate and prognosis (OR=20 for objective response RR=5.1 for PFS, 6.7 for OS)
 - No correlation in pts treated by CHT alone
- Selection of pts who would benefit from addition of bevacizumab to CHT avoiding overtreatment

Ravanelli et al ECR 2015



Final considerations

- Imaging insights in tumor biology
- Imaging reflects on large mm-scale the tumor phenotype resulting from complex interactions of several micro/nano scale factors
- Evidence on xenografts are quite strong but strongly dependent on histotype
- Standardization of techniques and large studies are needed in humans
- What does it mean? → Does it works?



Thank you

